A survey of clarithromycin monotherapy and long‐term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims

2019 ◽  
Vol 29 (4) ◽  
pp. 427-432
Author(s):  
Tomohide Iwao ◽  
Genta Kato ◽  
Isao Ito ◽  
Eiji Aramaki ◽  
Tomohiro Kuroda
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Lung Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Insurance Claims ◽  
Term Administration ◽  
Health Insurance Claims

scholarly journals Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan

2021 ◽  
pp. annrheumdis-2021-220439
Author(s):  
Ruriko Koto ◽  
Akihiro Nakajima ◽  
Hideki Horiuchi ◽  
Hisashi Yamanaka
Keyword(s):  
Uric Acid ◽  
Cohort Study ◽  
Health Insurance ◽  
Serum Uric Acid ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Disease Status ◽  
Insurance Claims ◽  
Health Insurance Claims ◽  
Gout Flare

ObjectivesIn patients with gout, treating to target serum uric acid levels (sUA) of ≤6.0 mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia. Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia.MethodsThis retrospective cohort study analysed the JMDC Claims Database from April 2012 through June 2019. Subjects with sUA ≥8.0 mg/dL were identified, and disease status (prescriptions for urate-lowering therapy (ULT), occurrence of gout flare, sUA) was investigated for 1 year. Time to first onset and incidence rate of gout flare were determined by disease status subgroups for 2 years or more. The relationship between gout flare and sUA control was assessed using multivariable analysis.ResultsThe analysis population was 19 261 subjects who met eligibility criteria. We found fewer occurrences of gout flare, for both gout and asymptomatic hyperuricaemia, in patients who achieved sUA ≤6.0 mg/dL with ULT than in patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. In particular, analysis by a Cox proportional-hazard model for time to first gout flare indicated that the HR was lowest, at 0.45 (95% CI 0.27 to 0.76), in subjects with asymptomatic hyperuricaemia on ULT (5.0<sUA ≤ 6.0 mg/dL), compared with untreated subjects (sUA ≥8.0 mg/dL).ConclusionsOccurrences of gout flare were reduced by controlling sUA at ≤6.0 mg/dL in subjects with asymptomatic hyperuricaemia as well as in those with gout.Trial registration numberUMIN000039985.

scholarly journals A Long-Term Incidence of Heart Failure and Predictors Following Newly Developed Acute Myocardial Infarction: A 10 Years Retrospective Cohort Study with Korean National Health Insurance Data

2021 ◽  
Vol 18 (12) ◽  
pp. 6207
Author(s):  
Hyojung Choi ◽  
Joo Yeon Seo ◽  
Jinho Shin ◽  
Bo Youl Choi ◽  
Yu-Mi Kim
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Cohort Study ◽  
Health Insurance ◽  
National Health Insurance ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Late Onset

Heart failure (HF) is the major mechanism of mortality in acute myocardial infarction (AMI) during early or intermediate post-AMI period. But heart failure is one of the most common long-term complications of AMI. Applied the retrospective cohort study design with nation representative population data, this study traced the incidence of late-onset heart failure since 1 year after newly developed acute myocardial infarction and assessed its risk factors. Methods and Results: Using the Korea National Health Insurance database, 18,328 newly developed AMI patients aged 40 years or older and first hospitalized in 2010 for 3 days or more, were set up as baseline cohort (12,403). The incidence rate of AMI per 100,000 persons was 79.8 overall, and 49.6 for women and 112.3 for men. A total of 2010 (1073 men, 937 women) were newly developed with HF during 6 years following post AMI. Cumulative incidences of HF per 1000 AMI patients for a year at each time period were 37.4 in initial hospitalization, 32.3 in 1 year after discharge, and 8.9 in 1–6 years. The overall and age-specific incidence rates of HF were higher in women than men. For late-onset HF, female, medical aid, pre-existing hypertension, severity of AMI, duration of hospital stay during index admission, reperfusion treatment, and drug prescription pattern including diuretics, affected the occurrence of late-onset HF. Conclusion: With respect to late-onset HF following AMI, appropriate management including hypertension and medical aid program in addition to quality improvement of AMI treatment are required to reduce the risk of late-onset heart failure.

scholarly journals Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e029641 ◽  
Author(s):  
Ayumi Takano ◽  
Sachiko Ono ◽  
Hayato Yamana ◽  
Hiroki Matsui ◽  
Toshihiko Matsumoto ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Health Insurance ◽  
Retrospective Cohort Study ◽  
Clinical Guidelines ◽  
Retrospective Cohort ◽  
Neurotic Disorder ◽  
Health Insurance Database ◽  
Insurance Database

ObjectivesCurrent clinical guidelines discourage long-term prescription of benzodiazepines and Z-drugs (BZD); however, the practice continues to exist. The aim of this study was to investigate the proportion of long-term BZD prescriptions and its risk factors.DesignRetrospective cohort study using a health insurance database.SettingJapan.ParticipantsA total of 86 909 patients were identified as outpatients aged 18 to 65 years who started BZD between 1 October 2012 and 1 April 2015. After excluding patients who underwent surgery on the day of first BZD prescription (n=762) and patients without 8 months follow-up (n=12 103), 74 044 outpatients were analysed.Main outcome measuresWe investigated the proportion of long-term prescriptions for ≥8 months among new BZD users. We assessed patient demographics, diagnoses, characteristics of the initial BZD prescription and prescribers as potential predictors of the long-term BZD prescription. Multivariable logistic regression was performed to assess the association between long-term prescription and potential predictors.ResultsOf the new BZD users, 6687 (9.0%) were consecutively prescribed BZD for ≥8 months. The long-term prescription was significantly associated with mood and neurotic disorder, cancer, prescription by psychiatrists, multiple prescriptions, hypnotics and medium half-life BZD in the initial prescription.ConclusionDespite the recent clinical guidelines, 9% of new BZD users were given prescriptions for more than 8 months. Physicians should be aware of risk factors when prescribing BZDs for the first time.

How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study

2018 ◽  
Vol 17 (11) ◽  
pp. 1124-1133 ◽  
Author(s):  
Christos F. Kampolis ◽  
Aliki I. Venetsanopoulou ◽  
Foteini Karakontaki ◽  
Vlasis Polychronopoulos ◽  
Panayiotis Vlachoyiannopoulos ◽  
...  
Keyword(s):  
Cohort Study ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Regional variation of care dependency after hip fracture in Germany: A retrospective cohort study using health insurance claims data

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0230648
Author(s):  
Claudia Schulz ◽  
Gisela Büchele ◽  
Raphael Simon Peter ◽  
Dietrich Rothenbacher ◽  
Patrick Roigk ◽  
...  
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Hip Fracture ◽  
Retrospective Cohort Study ◽  
Regional Variation ◽  
Retrospective Cohort ◽  
Claims Data ◽  
Insurance Claims Data ◽  
Health Insurance Claims Data ◽  
Health Insurance Claims
Sign in / Sign up

Export Citation Format

Share Document